LactobacillusModel Moiety a New Era Dosage Form as Nutraceuticals and Therapeutic Mediator

  • Abhinandan R. PatilEmail author
  • Sunita S. Shinde
  • Pratik S. Kakade
  • John I. D’souza
Part of the SpringerBriefs in Applied Sciences and Technology book series (BRIEFSAPPLSCIENCES)


In this era Bacteria are mostly considered as pathogenic. Bacteria though are pathogenic but still a few are friendly and essential for human growth and immunity; called as Probiotics. Lactobacillus model moiety is one of such probiotic bacterium which when introduced in sufficient colony serves as new prophylaxis and curing agent. This will increase the innate immunity of humans. Indian market lacks the quality uni-strain product of the probiotics as Nutraceuticals and as Health enhancing drug product. Global market is full of multi-strain microbes dosage form. The best mode to utilize Nutraceutical aspect of probiotics is to convert in dry form. These purified colony; later converted into the solid dry form by spray dry (JISL mini-spray drier) technique. Starch, lactose were used as thermo-protective agent while heat drying technique. Anti-microbial screenings carried out along with In vitro cytotoxicity studies. In vitro cytotoxicity screening evaluated that Lactobacillus powder showings anti-cancer activity nearly same as standard drug with no side effects. Dry powder increased the shelf life of the microbes that resulted in maintenance of viability and activity.


Lactobacillus model moiety Nutraceuticals Probiotics Pathogenic Uni-strain 


  1. 1.
    Vinderola G, Capellini B, Villarreal F, Suaŕez V, Quiberoni A, Reinheimer J (2008) Usefulness of a set of simple in vitro tests for the screening and identification of probiotic candidate strains for dairy use. J Food Sci Technol 41:1678–1688Google Scholar
  2. 2.
    Iannitti T, Palmieri B (2010) Therapeutical use of probiotic formulations in clinical practice. Clin Nutr 29:701–725CrossRefGoogle Scholar
  3. 3.
    Madhwani T, McBain A (2011) Bacteriological effects of a Lactobacillus reuteri probiotic on in vitro oral biofilms. Arch Oral Biol 56:1264–1273 CrossRefGoogle Scholar
  4. 4.
    Preidis G, Versalovic J (2009) Targeting the human microbiome with antibiotics probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 136:2015–2031CrossRefGoogle Scholar
  5. 5.
    Kaur I, Chopra K, Saini A (2002) Probiotics: potential pharmaceutical applications. Eur J Pharm Sci 15:1–9CrossRefGoogle Scholar
  6. 6.
    Gupta V, Garg R (2009) Probiotics. Indian J Med Microbiol 27(3):202–209CrossRefGoogle Scholar
  7. 7.
    Bernstein C et al (2009) Inflammatory bowel disease: a global perspective. World Gastroenterology Organisation Global Guidelines, USA, pp 1–24Google Scholar
  8. 8.
    Macfarlane S, Furrie E, Kennedy A, Cummings J, Macfarlane G (2005) Mucosal bacteria in ulcerative colitis. Br J Nutr 93:67–72CrossRefGoogle Scholar
  9. 9.
    Hatakka K, Holma R, El-Nezami H, Suomalainen T, Kuisma M, Saxelin M, Poussa T, Mykkänen H, Korpela R (2008) The influence of lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp. shermanii JS on potentially carcinogenic bacterial activity in human colon. Int J Food Microbiol 128:406–410CrossRefGoogle Scholar
  10. 10.
    Roller M, Clune Y, Collins K, Rechkemzer G, Watzl B (2007) Consumption of prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis has minor effects on selected immune parameters in polypectomised and colon cancer patients. Br J Nutr 97:676–684CrossRefGoogle Scholar
  11. 11.
    Rafter J, Bennett M, Caderni G, Clune Y, Hughes R, Karlsson C, Klinder A, O’Riordan M, O’Sullivan C, Pool-Zobel B, Rechkemmer G, Roller M, Rowland I, Salvadori M, Thijs H, Van Loo J, Watzl B, Collins K (2007) Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr 85:488–496Google Scholar
  12. 12.
    Liong M (2008) Safety of probiotics: translocation and infection. Nutr Rev 66(4):192–202CrossRefGoogle Scholar
  13. 13.
    Lewandowicz G, Harding B, Harkness W, Hayward R, Thomas DG, Darling L (2000) Chemosensitivity in childhood brain tumours in vitro: evidence of differential sensitivity to lomustine (CCNU) and vincristine. Cancer 36:1955–1964Google Scholar
  14. 14.
    Tanaka T (2009) Colorectal carcinogenesis: review of human and experimental animal studies. J Carcinog 8:1–19CrossRefGoogle Scholar
  15. 15.
    Tortora G, Grabowski S (2003) Principles of anatomy and physiology, 10th edn. Wiley, New Jersey, pp 853–855, pp 891–893Google Scholar
  16. 16.
    Levi E, Misra S, Du J, Patel B, Majumdar P (2009) Combination of aging and dimethylhydrazine treatment causes an increase in cancer—stem cell population of rat colonic crypts. Biochem Biophys Res Commun 385:430–433CrossRefGoogle Scholar
  17. 17.
    Ahmad S, Anjum F, Huma N, Sameen A, Zahoor T (2013) Composition and physico-chemical characteristics of buffalo milk with particular emphasis on lipids, proteins, minerals, enzymes and vitamins. J Anim Plant Sci 23:62–74Google Scholar
  18. 18.
    Shah NP, Ravula RR (2002) Microencapsulation of probiotic bacteria and their survival in frozen fermented dairy desserts. Aust J Dairy Technol 55(3):139–144CrossRefGoogle Scholar
  19. 19.
    Adhikari K, Mustapha A, Grun IU (2003) Survival and metabolic activity of microencapsulated Bifidobacterium longum in stirred yoghurt. J Food Sci 68(1):275–280CrossRefGoogle Scholar
  20. 20.
    Albertini B, Passerini N, Pattarino F, Rodriguez L (2008) New spray-congealing atomizer for the microencapsulation of highly concentrated solid and liquid substances. Eur J Pharm Biopharm Sci 69:348–357CrossRefGoogle Scholar
  21. 21.
    Albertini B, Passerini N, Di-Sabatino M, Vitali B, Brigidi P, Rodriguez L (2009) Polymer–lipid based mucoadhesive microspheres prepared by spray congealing for the vaginal delivery of Econazole nitrate. Eur J Pharm Sci 36:591–601CrossRefGoogle Scholar
  22. 22.
    Albertini B, Vitali B, Passerini N, Cruciani F, Di-Sabatino M, Rodriguez L, Brigidi P (2010) Development of microparticulate systems for intestinal delivery of Lactobacillus acidophilus and Bifidbacterium lactis. Eur J Pharm Sci 40:359–366CrossRefGoogle Scholar
  23. 23.
    Rault A, Bouix M, Béal C (2010) Cryotolerance of Lactobacillus delbrueckii subsp. bulgaricus CFL1 is influenced by the physiological state during fermentation. Int Dairy J 20:792–799CrossRefGoogle Scholar
  24. 24.
    Wargovich MJ et al (2000) Efficacy of potential chemopreventive agent on rat colon aberrant crypt formation and progression. Carcinogenesis 21(6):1149–1155CrossRefGoogle Scholar
  25. 25.
    Fasoli S et al (2003) Bacterial composition of commercial probiotic products as evaluated by PCR-DGGE analysis. Int J Food Microbiol 82:59–70CrossRefGoogle Scholar
  26. 26.
    Ananta E et al (2005) Cellular injuries and storage stability of spray-dried Lactobacillus rhamnosus GG. Int Dairy J 15:399–409CrossRefGoogle Scholar
  27. 27.
    Semyonov D et al (2010) Microencapsulation of Lactobacillus paracasei by spray freeze drying. J Food Res Int 43:193–202CrossRefGoogle Scholar
  28. 28.
    Albertini B et al (2010) Development of microparticulate systems for intestinal delivery of Lactobacillus acidophilus and Bifidobacterium lactis. Eur J Pharm Sci 40:359–366CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Authors and Affiliations

  • Abhinandan R. Patil
    • 1
    Email author
  • Sunita S. Shinde
    • 1
  • Pratik S. Kakade
    • 1
  • John I. D’souza
    • 1
  1. 1.Department of PharmaceuticsTatyasaheb Kore College of PharmacyWarananagar, KolhapurIndia

Personalised recommendations